Rare association between pancreatic insulinoma and Graves's disease: fortune or misfortune? Abstract #84

Introduction: In spite of low frequency ( 4 cases in 1 million population), insulimoma is a significant pathology because hypoglycemia causes severe neurologic lesions and death.
Aim(s): To present a case which illustrates the impact of a rare association to Graves’s disease on the clinical signs and diagnosis of insulinoma.
Materials and methods: Sixty-one-year-old female was referred in our endocrinology department with clinical signs of hyperthyroidism. The patient was evaluated for Graves’s disease by clinical exam and laboratory tests, such as routine biochemistry, TSH, fT4 and thyroid antibody measurements. Screening tests showed a decreased glucose blood level and fasting test with insulin measurement followed. We also used ultrasound and MRI for localization study.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Carmen Barbu

To read results and conclusion, please login ...

Further abstracts you may be interested in

#2737 Identification of a Novel MAFA Missense Mutation Causing Familial Insulinomatosis
Introduction: Insulinomatosis is a rare pancreatic disease characterized by an adult-onset condition of recurrent hyperinsulinemic hypoglycemia caused by multiple insulin-secreting neuroendocrine tumors.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: PD. Dr. Christian Fottner
#2761 Diagnosis and Management of Insulinomas. The Use of Current Practices in Pakistan
Introduction: Insulinomas are rare functional and benign neuroendocrine tumors of Pancreas.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Targeted therapies
Presenting Author: Dr Arooj Fatima
Authors: Fatima A, Zaidi S S A, ...
#2955 Development of an EORTC Quality of Life Questionnaire for Patients with Pancreatic Neuroendocrine Tumours: Phases 1-3
Introduction: Measuring quality of life (QoL) in Pancreatic Neuroendocrine Tumours (pNET) involves assessing issues from symptoms, disease and treatment. The validated gastrointestinal NETs module (EORTC QLQ-GINET21) is used with EORTC QLQ-C30 but there are concerns it inadequately measures QoL in pNET.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Non digestive NETs (bronchial, thymic, others) - diagnosis and therapy
Presenting Author: Elizabeth Friend
#1865 Evolution of Gastroenteropancreatic Neuroendocrine Tumors – Experiene of a Romanian Endocrine Clinic
Introduction: GEP-NETs (gastroenteropancreatic neuroendocrine tumors) are a heterogenous group of tumors.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: MD, PhD Ionela Baciu
Keywords: GEP-NETs
#2944 Soluble ST2 (sST2) Levels in the Management of Carcinoid Heart Disease in Patients with Neuroendocrine Cancer
Introduction: The identification of a sensitive biomarker to detect the presence and severity of carcinoid heart disease could allow more selective use of clinical and echocardiographic screening. ST2 is a protein belonging to the family of interleukin 1 receptors, present both in the isoform of transmembrane (ST2L) and in the soluble one (sST2). sST2 blocks the anti-inflammatory, anti-hypertrophic, and anti-fibrotic effects of cytokine IL-33 on the myocardium and recent studies have shown that sST2 levels increase in the blood of patients diagnosed with heart failure.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Biomarkers
Presenting Author: Daniela Maria Cardinale